3/2/2023 0 Comments Outset medical newsThanks to industry tailwinds such as the shift to home care aided by reimbursements, Outset Medical ( OM ) is positioned to generate 46% and 39% CAGR for 3-year and 5-year periods, the best in MedTech, the analysts added. This compares to loss of 0.56 per share a year ago. (Nasdaq: OM) ('Outset') announced today that the Strategic Acquisition Center (SAC) Office of Procurement, Department. (OM) came out with a quarterly loss of 0.67 per share versus the Zacks Consensus Estimate of a loss of 0.66. After the activity, the stock price went down -4.60 to 16.78. SAN JOSE, Calif., Aug- ( BUSINESS WIRE )- Outset Medical, Inc. (NASDAQ: OM) experienced volatile short activity. “In our view, OM is significantly undervalued given the opportunities ahead,” the team wrote, issuing a $23 per share target on the stock. On Friday, shares of Outset Medical, Inc. RBC analysts led by Shagun Singh think that Outset Medical ( OM ), which offers technology to lower the cost and complexity of dialysis, has the potential to cater to an $11B total addressable market for kidney failure in the U.S. (OM) delivered earnings and revenue surprises of -14.93 and 6.04, respectively, for the quarter ended December 2021. The class action is on behalf of shareholders who purchased Outset Medical securities between. (Nasdaq: OM) (Outset), a medical technology company reducing the cost and complexity of dialysis, announced the release of. (Outset Medical or the Company) (NASDAQ: OM). SAN JOSE, Calif.-(BUSINESS WIRE)-Today, Outset Medical, Inc. Outset Medical ( OM ), which develops a hemodialysis system, has lost ~64% over the past 12 months, underperforming its peers in the dialysis market, such as DaVita ( DVA ), Fresenius Medical Care ( FMS ) as indicated in this graph. SAN DIEGO, J(GLOBE NEWSWIRE) Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Outset Medical, Inc. MedTech company Outset Medical (NASDAQ: OM ) stretched the post-earnings rally to the third straight session on Friday after RBC Capital Markets launched its coverage with an Outperform recommendation pointing to its undervaluation. Outset Medical extends gains as RBC Capital Markets initiates at Outperform Outset Medical is a pioneering medical technology company reimagining dialysis for.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |